International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ‐HN43: Phase IV

• DOI: 10.1002/hed.25609
• Publication Date: 2019-01-12T17:04:45Z
• Authors: Susanne Singer; Cecilie Delphin A...; Eva Hammerlid; Iwona M. Tomaszewska; Joaquim Castro Silva; Hisham Mehanna; Marcos Santos; Johanna Inhestern; Christine Brannan; Noam Yarom; Amy Fullerton; Monica Pinto; Juan I. Arraras; Naomi Kiyota; Pierluigi Bonomo; Allen C. Sherman; Ingo Baumann; Razvan Galalae; Loreto Fernandez ...; Ourania Nicolatou...; Zeinab Abdel‐Hafeez; Judith Raber‐Durl...; Claudia Schmalz; Paola Zotti; Andreas Boehm; Dirk Hofmeister; Sanja Krejovic Tr...; Suat Loo; Wei‐Chu Chie; Kristin Bjordal; Bente Brokstad He...; Vincent Grégoire; Lisa Licitra
• Keywords: Discriminant validity

Abstract Background We validated the new European Organisation for Research and Treatment of Cancer Quality Life Head Neck Module (EORTC QLQ‐HN43). Methods enrolled 812 patients with head neck cancer from 18 countries. Group 1 completed questionnaire before therapy, 3 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed Cronbach's Alpha, scale structure confirmatory factor analysis, discriminant validity known‐group comparisons. Results alpha >0.70 in 10 12 multi‐item scales. All standardized loadings exceeded 0.40. The ICC all but two Differences scores between known‐groups were >10 points 17 19 Sensitivity to change found be sufficient Conclusions Evidence supports EORTC QLQ‐HN43 as a measure quality life.